Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $91.9K in total
- 2
- 13F holdersQ2 2026, −3 vs. previous quarter
- 45
- 13F valueReported value at the end of Q2 2026
- $3.91M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding HOWL, Q2 2026
No superinvestor reported holding HOWL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Werewolf Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 (view filing)5:34 PM ET | Jul 6-7 | 2 days | Evnin LukeDirector | SSale | −143.2K | $0.3125 | −$44.7K | −100.0%0 after | 2 lots10b5-1 |
| Jun 29, 2026 (view filing)7:07 PM ET | Jun 29 | Same day | Evnin LukeDirector | SSale | −157.1K | $0.30 | −$47.1K | −52.3%143.2K after | 10b5-1 |
| Jun 22, 2026 (view filing)6:59 PM ET | Jun 17 | 5 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −416.9K | $0.35 | −$145.9K | −57.9%303.7K after | 2 lots |
| Jun 16, 2026 (view filing)6:01 PM ET | Jun 12-16 | 4 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −448.8K | $0.3871 | −$173.8K | −57.5%331.4K after | 6 lots |
| Jun 11, 2026 (view filing)8:13 PM ET | Jun 9-11 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −678.2K | $0.3739 | −$253.6K | −65.2%361.2K after | 6 lots |
| Jun 10, 2026 (view filing)5:20 PM ET | Jun 9 | 1 day | Evnin LukeDirector | SSale | −76.9K | $0.37 | −$28.5K | −20.4%300.3K after | 10b5-1 |
| Jun 8, 2026 (view filing)6:13 PM ET | Jun 4-8 | 4 days | Evnin LukeDirector | SSale | −105.6K | $0.4076 | −$43.0K | −21.9%377.2K after | 3 lots10b5-1 |
| Jun 3, 2026 (view filing)6:42 PM ET | Jun 1-3 | 2 days | Evnin LukeDirector | SSale | −139.8K | $0.4551 | −$63.6K | −22.5%482.8K after | 3 lots10b5-1 |
| May 29, 2026 (view filing)6:51 PM ET | May 27-29 | 2 days | Evnin LukeDirector | SSale | −141.1K | $0.4692 | −$66.2K | −18.5%622.6K after | 3 lots10b5-1 |
| May 26, 2026 (view filing)6:18 PM ET | May 21-26 | 5 days | Evnin LukeDirector | SSale | −191.8K | $0.4514 | −$86.6K | −20.1%763.7K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Werewolf Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 2,387,744 | $859.3K | 0.01% | −4,293,563−64.3% | Reduced |
| Balyasny Asset Management LLC | 1,790,089 | $644.3K | 0.00% | +1,790,089 | New |
| Vanguard Capital Management LLC | 1,217,976 | $438.5K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 674,632 | $242.8K | 0.00% | +158,414+30.7% | Added |
| Lynx1 Capital Management LP | 657,786 | $236.7K | 0.03% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 626,810 | $225.6K | 0.03% | 00.0% | Unchanged |
| DC Funds, LP | 589,102 | $212.0K | 16.92% | 00.0% | Unchanged |
| Verdad Advisers, LP | 348,709 | $125.5K | 0.12% | +318,949+1,071.7% | Added |
| Geode Capital Management, LLC | 335,815 | $120.9K | 0.00% | −53,672−13.8% | Reduced |
| Bank of America Corp | 311,502 | $111.8K | 0.00% | +46,919+17.7% | Added |